Company profile
REZOLUTE, INC.
NASDAQ:RZLTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ERSODETUG | phase3 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06881992 | phase3 | recruiting | 2025-04-16 | 2027-09-01 | Rezolute | A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism |
| NCT04538989 | phase2 | completed | 2020-02-24 | 2022-04-05 | Rezolute | An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism |
| NCT06208215 | phase3 | active_not_recruiting | 2024-01-11 | 2025-11-14 | Rezolute | RZ358 Treatment for Congenital Hyperinsulinism |
| NCT05712720 | phase2 | completed | 2023-02-06 | 2024-04-11 | Rezolute | Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME) |
FDA applications (0)
No records yet.